^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Adenocarcinoma
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ABRAXANE is a microtubule inhibitor indicated for the treatment of...Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pancreatic Adenocarcinoma: Preferred Regimens…Gemcitabine + albumin-bound paclitaxel
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    N Engl J Med
    Title:

    Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Published date:
    10/31/2013
    Excerpt:
    A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430).The median overall survival was 8.5 months in the nab-paclitaxel–gemcitabine group as compared with 6.7 months in the gemcitabine group...The survival rate was 35% in the nab-paclitaxel–gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel–gemcitabine group, as compared with 3.7 months in the gemcitabine group...In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate...
    DOI:
    10.1056/NEJMoa1304369
    Trial ID:
    NCT00844649